{"id":"fenoverine","rwe":[{"pmid":"37788098","year":"2023","title":"Pharmacotherapy for gastric and intestinal cramping pain: ‎ current and emerging therapies.","finding":"","journal":"Expert opinion on pharmacotherapy","studyType":"Clinical Study"},{"pmid":"33617948","year":"2021","title":"In silico identification of available drugs targeting cell surface BiP to disrupt SARS-CoV-2 binding and replication: Drug repurposing approach.","finding":"","journal":"European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences","studyType":"Clinical Study"},{"pmid":"32334639","year":"2020","title":"The incidence, risk factors, and clinical outcomes of rhabdomyolysis associated with fenoverine prescription: a retrospective study in South Korea (1999-2014).","finding":"","journal":"BMC pharmacology & toxicology","studyType":"Clinical Study"},{"pmid":"24262593","year":"2013","title":"[Efficacy of fenoverine and trimebutine in the management of irritable bowel syndrome: multicenter randomized double-blind non-inferiority clinical study].","finding":"","journal":"The Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi","studyType":"Clinical Study"},{"pmid":"22672854","year":"2012","title":"Effect of antispasmodic agents, alone or in combination, in the treatment of Irritable Bowel Syndrome: systematic review and meta-analysis.","finding":"","journal":"Revista de gastroenterologia de Mexico","studyType":"Clinical Study"}],"tags":[{"label":"fenoverine","category":"class"},{"label":"Small Molecule","category":"modality"},{"label":"A03AX05","category":"atc"},{"label":"Active","category":"status"},{"label":"Parasympatholytics","category":"pharmacology"},{"label":"Peripheral Nervous System Agents","category":"pharmacology"}],"phase":"phase_3","safety":{},"trials":[],"aliases":[],"patents":[],"pricing":[],"allNames":"spasmopriv","offLabel":[],"synonyms":["fenoverine","spasmopriv"],"timeline":[],"approvals":[],"brandName":"Spasmopriv","ecosystem":[],"mechanism":{"modality":"Small Molecule","drugClass":"fenoverine","explanation":"Imagine your nervous system as a balance between two opposing forces: the sympathetic nervous system, which is like the accelerator in a car, and the parasympathetic nervous system, which is like the brake. Fenoverine helps to calm down the parasympathetic nervous system, which can help to relieve muscle spasms and other conditions.","oneSentence":"Fenoverine works by interacting with the muscarinic acetylcholine receptor, a key component in the parasympathetic nervous system.","technicalDetail":"Fenoverine is a muscarinic receptor antagonist that selectively binds to the M3 subtype, inhibiting the acetylcholine-mediated contraction of smooth muscle and glandular secretion."},"commercial":{},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/1156","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://clinicaltrials.gov/search?intr=FENOVERINE","fields":["trials"],"source":"ClinicalTrials.gov"},{"id":3,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=FENOVERINE","fields":["publications"],"source":"PubMed/NCBI"}],"_enrichedAt":"2026-03-30T11:25:47.361368","_validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T08:42:02.854260+00:00","fieldsConflicting":0,"overallConfidence":0.95},"biosimilars":[],"competitors":[{"drugName":"isometheptene","drugSlug":"isometheptene","fdaApproval":"","relationship":"same-class"}],"genericName":"fenoverine","indications":{"approved":[],"offLabel":[],"pipeline":[]},"drugCategory":"active","labelChanges":[],"relatedDrugs":[{"drugId":"isometheptene","brandName":"isometheptene","genericName":"isometheptene","approvalYear":"","relationship":"same-class"}],"trialDetails":[{"nctId":"NCT01507922","phase":"PHASE4","title":"Comparative Efficacy and Safety of Fenoverine","status":"COMPLETED","sponsor":"Bukwang Pharmaceutical","startDate":"2011-12","conditions":["Irritable Bowel Syndrome"],"enrollment":186,"completionDate":"2013-06"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"crossReferences":{"NDDF":"005418","UNII":"N274ZQ6PZJ","CHEBI":"CHEBI:135744","INN_ID":"3288","RXNORM":"24855","UMLSCUI":"C0060182","ChEMBL_ID":"CHEMBL1512949","KEGG_DRUG":"D07095","DRUGBANK_ID":"DB13042","PUBCHEM_CID":"72098","MESH_SUPPLEMENTAL_RECORD_UI":"C048314"},"formularyStatus":[],"_enricherVersion":"v2","developmentCodes":[],"ownershipHistory":[],"publicationCount":25,"therapeuticAreas":["Other"],"atcClassification":{"source":"DrugCentral","atcCode":"A03AX05","allCodes":["A03AX05"]},"biosimilarFilings":[],"recentPublications":[{"date":"2023 Sep-Dec","pmid":"37788098","title":"Pharmacotherapy for gastric and intestinal cramping pain: ‎ current and emerging therapies.","journal":"Expert opinion on pharmacotherapy"},{"date":"2021 May 1","pmid":"33617948","title":"In silico identification of available drugs targeting cell surface BiP to disrupt SARS-CoV-2 binding and replication: Drug repurposing approach.","journal":"European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences"},{"date":"2020 Apr 25","pmid":"32334639","title":"The incidence, risk factors, and clinical outcomes of rhabdomyolysis associated with fenoverine prescription: a retrospective study in South Korea (1999-2014).","journal":"BMC pharmacology & toxicology"},{"date":"2013 Nov","pmid":"24262593","title":"[Efficacy of fenoverine and trimebutine in the management of irritable bowel syndrome: multicenter randomized double-blind non-inferiority clinical study].","journal":"The Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi"},{"date":"2012 Apr-Jun","pmid":"22672854","title":"Effect of antispasmodic agents, alone or in combination, in the treatment of Irritable Bowel Syndrome: systematic review and meta-analysis.","journal":"Revista de gastroenterologia de Mexico"}],"companionDiagnostics":[],"genericManufacturerList":[],"status":"active","companyName":"","companyId":"","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Spasmopriv, also known as Fenoverine, is a small molecule drug in the fenoverine class. Its exact target is unknown, but it is used to treat certain conditions. Unfortunately, there is limited information available on its commercial status, approved indications, and pharmacokinetic properties. Further research is needed to fully understand its mechanism of action and safety profile. As a result, it is not widely used or recognized in the pharmaceutical industry.","enrichmentLevel":5,"visitCount":0,"trialStats":{"total":0,"withResults":0},"validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T08:42:02.854260+00:00","fieldsConflicting":0,"overallConfidence":0.95},"verificationStatus":"partial","dataCompleteness":{"mechanism":true,"indications":false,"safety":false,"trials":true,"score":2}}